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Table S 1 Overview of codes used to define each cardiovascular endpoints and data sources. Details of how these codes are combined are given in the CALIBER data 
portal 
Endpoint CPRD – Read codes MINAP – specific 
disease registry 
HES – OPCS 4 hospital 
procedures 
HES – ICD 10 hospital diagnoses† ONS – ICD 10 causes of death‡ 
Stable angina G33..00: Stable Angina 
G33z.00: Angina pectoris NOS + 19 other Read 
codes for diagnosis of stable angina pectoris. 
G33z400: Ischaemic chest pain 
Coded test results associated with 33 Read codes 
for coronary angiography or 
139 Read codes for myocardial ischaemia tests 
(resting ECG, exercise ECG, stress echo, 
radioisotope scan) 
57 Read codes for coronary artery bypass graft 
28 Read codes for percutaneous coronary 
intervention 
Two or more successive prescriptions for anti-
anginals. 
nu K40-K46: Coronary artery 
bypass graft. 
K49, K50 and K75: 
Percutaneous coronary 
intervention 
I20.1: Angina pectoris with documented 
spasm 
I20.8: Other forms of angina pectoris 
I20.9: Angina pectoris, unspecified 
nu 
Unstable angina G311500: Acute coronary syndrome 
G311100: Unstable angina + 10 other Read codes 
for unstable angina  
 
Discharge diagnosis of 
acute coronary 
syndrome without 
raised troponin 
. 
Lack of coronary artery 
bypass graft or percutaneous 
coronary intervention record 
in the same hospital spell as 
I20.9 implies admission for 
unstable angina 
I20.0: Unstable angina. 
I24.0: Coronary thrombosis not resulting in 
MI.  
I24.8: Other forms of ischaemic heart 
disease. 
I24.9: Acute ischaemic heart disease, 
unspecified. 
‘I20.9: Angina pectoris, unspecified’ 
without coronary artery bypass graft or 
percutaneous coronary intervention in the 
same hospital spell 
nu 
Coronary heart 
disease not 
otherwise specified 
G3...00: Ischaemic heart disease + 29 other Read 
codes 
nu nu I25 (CHD NOS, chronic ischaemic  heart 
disease, silent MI) except ‘I25.2: Old MI’ 
nu 
2 
 
Non-fatal acute 
Myocardial 
Infarction (MI) 
 
G30X000: Acute ST segment elevation 
myocardial infarction. 
G307100: Acute non-ST segment elevation 
myocardial infarction. 
G30..15: MI Acute myocardial infarction + 53 
other Read codes 
7929100: Percut transluminal coronary 
thrombolysis with streptokinase + 3 other Read 
codes for coronary thrombolysis 
Elevated cardiac markers, troponin or CKMB 
results associated with 16 Read codes 
 
MI with or without ST 
elevation based on 
initial ECG findings, 
raised troponins and 
clinical diagnosis. 
K50.2: Percutaneous 
transluminal coronary 
thrombolysis using 
streptokinase 
K50.3: Percutaneous 
transluminal injection of 
therapeutic substance into 
coronary artery NEC  
I21: Acute MI. 
I22: Subsequent MI 
 
nu 
Unheralded 
coronary death 
Any CVD excluded. Any CVD excluded. Any CVD excluded. Any CVD excluded. I20-I25: Ischaemic heart disease 
Heart failure  G58..00: Heart Failure + 40 other Read codes for 
heart failure  
585f.00: Echocardiogram shows left ventricular 
systolic dysfunction 
585g.00: Echocardiogram shows left ventricular 
diastolic dysfunction 
nu nu I11.0: Hypertensive heart disease with 
(congestive) heart failure 
I13.0: Hypertensive heart and renal disease 
with (congestive) heart failure 
I13.2: Hypertensive heart and renal disease 
with both (congestive) heart failure and 
renal disease 
I50: Heart failure 
I11.0 Hypertensive heart disease 
with (congestive) heart failure 
I13.0: Hypertensive heart and renal 
disease with (congestive) heart 
failure 
I13.2: Hypertensive heart and renal 
disease with both (congestive) heart 
failure and renal disease 
I50 Heart failure 
 
Ventricular 
arrhythmias, 
cardioversion, 
cardiac arrest and 
sudden cardiac 
death 
G757.00: Cardiac arrest + 30 other Read codes 
for ventricular fibrillation, asystole, cardiac arrest, 
cardiac resuscitation 
G575100: Sudden cardiac death, so described 
 
nu X50: External resuscitation. 
K59: Cardioverter 
defibrillator introduced 
through the vein 
I46.0: Cardiac arrest with successful 
resuscitation 
I46.1: Sudden cardiac death, so described 
I46.9: Cardiac arrest, unspecified 
I47.0: Re-entry ventricular arrhythmia 
I47.2: Ventricular tachycardia 
I49.0: Ventricular fibrillation and flutter 
 
 
I46.0: Cardiac arrest with successful 
resuscitation 
I46.1: Sudden cardiac death, so 
described 
I46.9: Cardiac arrest, unspecified 
I47.0: Re-entry ventricular 
arrhythmia 
I47.2: Ventricular tachycardia 
I49.0: Ventricular fibrillation and 
flutter 
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Transient 
ischaemic attack 
G65..12: Transient ischaemic attack + 5 other 
Read codes 
nu nu G45.8-G45.9: Transient cerebral ischaemic 
attack 
nu 
Ischaemic stroke G64..11: CVA – cerebral artery occlusion + 9 
other Read codes 
7A20311: Carotid endarterectomy and patch + 4 
other Read codes for carotid endarterectomy 
within 90 days of stroke not otherwise specified 
denote ischaemic stroke  
nu L29.5: Endarterectomy of 
carotid artery NEC + 3 other 
codes for carotid 
endarterectomy or stenting 
within 90 days of stroke not 
otherwise specified denote 
ischaemic stroke 
I63: Cerebral infarction. I63: Cerebral infarction. 
Stroke not 
otherwise specified 
G66..00: Stroke and cerebrovascular accident 
unspecified + 14 other Read codes 
nu U54.3 Delivery of 
rehabilitation for stroke 
I64: Stroke, not specified as haemorrhage or 
infarction 
G46.3-G46.7: Stroke syndromes  
I64: Stroke, not specified as 
haemorrhage or infarction 
I67.2: Cerebral atherosclerosis 
I67.9: Cerebrovascular disease, 
unspecified 
Subarachnoid 
haemorrhage 
G60X.00: Subarachnoid haemorrh from 
intracranial artery, unspecif + 2 other Read codes 
for subarachnoid haemorrhage 
nu Nu I60: Subarachnoid haemorrhage. I60: Subarachnoid haemorrhage. 
Intracerebral 
haemorrhage 
G61..00: Intracerebral haemorrhage + 16 other 
Read codes for intracerebral haemorrhage. 
nu nu I61: Intracerebral haemorrhage. I61: Intracerebral haemorrhage. 
Peripheral arterial 
disease 
63 codes for Lower limb peripheral arterial 
disease diagnosis (including diabetic PAD, 
gangrene and intermittent claudication). 
136 Read codes for peripheral arterial disease 
procedures 
2 Read codes for abnormal lower limb angiogram 
nu L50-L54: Bypass, 
reconstruction and other open 
operations on iliac artery. 
 L58-L60, L62: Bypass, 
reconstruction, transluminal 
operations or other open 
operations of femoral artery. 
 L65: Revision of 
reconstruction of artery. 
 
I73.1: Thromboangiitis obliterans 
I73.8: Other specified peripheral vascular 
diseases 
I73.9: Peripheral vascular disease, 
unspecified 
I74.3: Embolism and thrombosis of arteries 
of lower extremities 
I74.4: Embolism and thrombosis of arteries 
of extremities, unspecified 
I74.5: Embolism and thrombosis of iliac 
artery 
I73.1: Thromboangiitis obliterans 
I73.8: Other specified peripheral 
vascular diseases 
I73.9: Peripheral vascular disease, 
unspecified 
I74.3: Embolism and thrombosis of 
arteries of lower extremities 
I74.4: Embolism and thrombosis of 
arteries of extremities, unspecified 
I74.5: Embolism and thrombosis of 
iliac artery 
4 
 
Abdominal aortic 
aneurysm 
G714.00: Abdominal aortic aneurysm without 
mention of rupture + 12 other Read codes 
nu L18: Emergency replacement 
of aneurysmal segment of 
aorta 
L19:  Other replacement of 
aneurysmal segment of aorta 
L20: Other emergency 
bypass of segment of aorta 
L254: Operations on 
aneurysm of aorta NEC 
L27: Transluminal insertion 
of stent graft for aneurysmal 
segment of aorta 
L28: Transluminal operations 
on aneurysmal segment of 
aorta  
I71.3: Abdominal aortic aneurysm, ruptured 
I71.4: Abdominal aortic aneurysm, without 
mention of rupture 
I71.5: Thoracoabdominal aortic aneurysm, 
ruptured 
I71.6: Thoracoabdominal aortic aneurysm, 
without mention of rupture 
I71.8: Aortic aneurysm of unspecified site, 
ruptured 
I71.9: Aortic aneurysm of unspecified site, 
without mention of rupture 
  
I71.3: Abdominal aortic aneurysm, 
ruptured 
I71.4: Abdominal aortic aneurysm, 
without mention of rupture 
I71.5: Thoracoabdominal aortic 
aneurysm, ruptured 
I71.6: Thoracoabdominal aortic 
aneurysm, without mention of 
rupture 
I71.8: Aortic aneurysm of 
unspecified site, ruptured 
I71.9: Aortic aneurysm of 
unspecified site, without mention of 
rupture 
  
 
Note: AAA, aortic abdominal aneurysm; MI, myocardial infarction; nu = not used in definition.  
†Primary cause of admission.  
‡Underlying cause of death. 
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Table S 2 Cohort summary characteristics
1,2,3
. 
 
SBP <115 & DBP 
<75 mmHg 
SBP 115-139 or DBP 
75-89 mmHg 
SBP 140-159 or DBP 
90-99 mmHg 
SBP >160 or >100 
mmHg 
N patients 202,435  638,658  313,748  103,165  
Age, years 38.7 (10.0) 44.9 (13.6) 56.4 (15.0) 63.9 (14.5) 
Female sex 155,617 (76.9%) 362,678 (56.8%) 156,672 (49.9%) 57,690 (55.9%) 
White ethnicity 99,397 (84.4%) 322,704 (88.9%) 173,824 (93.1%) 60,237 (95.2%) 
Most deprived quintile 42,342 (20.9%) 127,486 (20.0%) 60,446 (19.3%) 21,164 (20.5%) 
Smoking  status4 
    Ex-smoker 26,524 (15.1%) 92,996 (16.9%) 51,381 (19.8%) 14,266 (17.9%) 
Current smoker 43,814 (24.9%) 129,724 (23.6%) 47,217 (18.2%) 12,053 (15.1%) 
Medical history 
    Diabetes 1,907 (0.9%) 20,198 (3.2%) 17,685 (5.6%) 5,912 (5.7%) 
Kidney disease 1,593 (0.8%) 7,215 (1.1%) 4,679 (1.5%) 1,280 (1.2%) 
COPD 1,773 (0.9%) 9,436 (1.5%) 7,847 (2.5%) 3,121 (3.0%) 
Measurements4 
    Body mass index, kg/m2 23.1 (21.1-25.7) 25.6 (22.9-28.8) 27.3 (24.4-30.9) 27.5 (24.4-31.2) 
Total cholesterol, mmol/L 5.0 (4.3-5.7) 5.2 (4.5-6.0) 5.4 (4.7-6.2) 5.7 (4.9-6.4) 
HDL cholesterol, mmol/L 1.4 (1.2-1.7) 1.3 (1.1-1.6) 1.3 (1.1-1.6) 1.3 (1.1-1.6) 
Systolic blood pressure, mmHg 
106.7 (5.9) 125.1 (7.7) 146.2 (6.6) 167.2 (11.5) 
Diastolic blood pressure, mmHg 
66.7 (5.1) 77.6 (6.3) 85.5 (7.0) 91.6 (9.3) 
Isolated systolic hypertension 0 (0.0%) 0 (0.0%) 208,081 (66.3%) 41,405 (40.1%) 
Isolated diastolic hypertension 355 (0.2%) 14,395 (2.3%) 18,670 (6.0%) 1,004 (1.0%) 
Statins 1,570 (0.8%) 21,526 (3.4%) 19,798 (6.3%) 4,010 (3.9%) 
Blood pressure lowering treatments 
21,643 (10.7%) 113,436 (17.8%) 139,753 (44.5%) 66,086 (64.1%) 
    Thiazide diuretics 746 (0.4%) 16,593 (2.6%) 42,662 (13.6%) 22,964 (22.3%) 
    Beta-blockers 3,443 (1.7%) 25,632 (4.0%) 36,367 (11.6%) 17,565 (17.0%) 
    ACEI/ARBs 1,572 (0.8%) 25,491 (4.0%) 43,784 (14.0%) 19,760 (19.2%) 
    Calcium-channel blockers 454 (0.2%) 11,826 (1.9%) 28,232 (9.0%) 14,419 (14.0%) 
Number of baseline BP 
measurements 2 (1-3) 2 (1-3) 3 (1-7) 4 (1-9) 
    
1
 Patients are classified to the highest category based on their SBP or DBP. 
2
Continuous variables are summarized as median (inter-quartile range), except for systolic and diastolic blood pressure, summarized as 
mean (standard deviation). Categorical variables are summarized as number (% in the corresponding blood pressure category).  
3
 Patients with missing baseline blood pressure measurements (N=679,354) were excluded. 
4
 Missing data (%): Smoking status, 15%; Body mass index, 56%; Total cholesterol, 80%; HDL cholesterol, 84%. 
Abbreviations: ACEI, Angiotensin-converting enzyme inhibitors; ARBs, Alpha-adrenoreceptor blocking drugs; COPD, chronic 
obstructive pulmonary disease; HDL, high-density lipoprotein cholesterol. 
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Table S 3 Summary characteristics of people with recorded (main analysis dataset) and missing blood pressure among eligible 
patients (N=1,937,360).  
 
  
Baseline BP recorded 
(N=1,258,006) 
Baseline BP missing 
(N=679,354) 
P-value for 
difference* 
Age, years 45.0 (34.9-58.9) 40.6 (32.0-52.5) P<0.0001 
Female sex 732,657 (58.2%) 238,561 (35.9%) P<0.0001 
White ethnicity 656,162 (89.8%) 254,958 (92.2%) P<0.0001 
Most deprived quintile 251,438 (20.0%) 136,206 (20.5%) P<0.0001 
Smoking  status 
   Ex-smoker 185,167 (17.4%) 41,728 (12.4%) P<0.0001 
Current smoker 232,808 (21.8%) 52,550 (15.6%) P<0.0001 
Medical history 
   Diabetes 45,702 (3.6%) 3,064 (0.5%) P<0.0001 
Kidney disease 14,767 (1.2%) 2,728 (0.4%) P<0.0001 
COPD 22,177 (1.8%) 7,308 (1.1%) P<0.0001 
Measurements 
   Body mass index, kg/m
2
 25.6 (22.8-29.0) 24.9 (22.3-28.3) P<0.0001 
Total cholesterol, mmol/L 
5.3 (4.6-6.1) 5.3 (4.6-6.1) P=0.10 
HDL cholesterol, mmol/L 1.3 (1.1-1.6) 1.3 (1.1-1.6) P=0.03 
Medication use 
   Thiazide diuretics 82,965 (6.6%) 6,451 (1.0%) P<0.0001 
Beta-blockers 83,007 (6.6%) 9,320 (1.4%) P<0.0001 
ACEI/ARBs 90,607 (7.2%) 5,449 (0.8%) P<0.0001 
Calcium-channel blockers 54,931 (4.4%) 3,203 (0.5%) P<0.0001 
Statins 46,904 (3.7%) 1,568 (0.2%) P<0.0001 
 
*Two-sided, with Bonferroni correction for multiple comparisons. 
Continuous variables are summarised as median (IQR) and categorical as N (%). 
Abbreviations: ACEI, Angiotensin-converting enzyme inhibitors; ARBs, Alpha-adrenoreceptor blocking drugs; COPD, chronic 
obstructive pulmonary disease; HDL, high-density lipoprotein cholesterol. 
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Table S 4 Estimates of lifetime risks and life-years lost to CVD associated with hypertension at different index ages (30, 60, 80) 
up to age 95. 
EVENTS 
Lifetime risks 
Life-years lost to CVD 
 
Normotensives Hypertensives 
Lifetime risk 
difference 
Lifetime risk ratio All hypertensives 
Isolated systolic 
hypertension 
Isolated diastolic 
hypertension 
Index age 30   
 
 
    
 
  
Stable angina 
4.9  (4.7-5.2) 8.9  (8.7-9.2) 4.0 (3.7, 4.3) 1.82 (1.76-1.87) 1.11 (1.03,1.19) 0.3 (0.26,0.33) 0.02 (-0.01,0.04) 
Unstable angina 
6.7  (6.4-7.0) 10.1  (9.8-10.3) 3.4 (3.0, 3.7) 1.5 (1.46-1.55) 1.04 (0.95,1.13) 0.21 (0.17,0.25) 0.01 (-0.01,0.04) 
Myocardial infarction 
5.5  (5.3-5.8) 8.0  (7.8-8.3) 2.5 (2.2, 2.8) 1.45 (1.41-1.49) 0.75 (0.67,0.83) 0.21 (0.17,0.25) 0.06 (0.03,0.08) 
Unheralded CHD death 
1.9  (1.8-2.1) 2.5  (2.4-2.6) 0.6 (0.3, 0.8) 1.29 (1.22-1.36) 0.15 (0.11,0.2) 0.04 (0.02,0.05) 0.03 (0.01,0.05) 
Heart failure 
5.2  (4.9-5.6) 7.8  (7.6-8.1) 2.6 (2.2, 3.0) 1.5 (1.44-1.55) 0.58 (0.51,0.64) 0.1 (0.07,0.13) 0.04 (0.02,0.07) 
Cardiac arrest/SCD 
1.8  (1.7-2.0) 2.3  (2.2-2.4) 0.5 (0.3, 0.7) 1.26 (1.17-1.34) 0.16 (0.11,0.2) 0.01 (-0.01,0.03) 0.03 (0.00,0.05) 
Transient ischaemic attack 
5.9  (5.6-6.2) 6.5  (6.3-6.7) 0.6 (0.3, 1.0) 1.11 (1.07-1.14) 0.26 (0.18,0.33) 0.06 (0.03,0.09) 0.02 (0.00,0.05) 
Ischaemic stroke 
6.5  (6.2-6.9) 7.6  (7.3-7.8) 1.0 (0.7, 1.4) 1.16 (1.12-1.2) 0.35 (0.27,0.42) 0.06 (0.03,0.09) 0.00 (-0.03,0.03) 
Subarachnoid haemorrhage 
0.6  (0.5-0.7) 0.9  (0.7-1.0) 0.3 (0.2, 0.4) 1.48 (1.27-1.68) 0.09 (0.06,0.12) 0.04 (0.02,0.05) 0.00 (-0.01,0.01) 
Intracerebral haemorrhage 
0.9  (0.8-1.0) 1.3  (1.2-1.4) 0.4 (0.2, 0.5) 1.4 (1.29-1.51) 0.1 (0.07,0.14) 0.03 (0.02,0.04) 0.00 (-0.01,0.02) 
Peripheral arterial disease 
4.5  (4.2-4.7) 5.8  (5.6-6.0) 1.3 (1.0, 1.6) 1.3 (1.25-1.34) 0.4 (0.33,0.46) 0.14 (0.11,0.17) -0.01 (-0.03,0.01) 
Abdominal aortic aneurysm 
1.5  (1.4-1.7) 1.6  (1.5-1.7) 0.1 (-0.1, 0.3) 1.05 (0.97-1.13) 0.04 (0,0.07) -0.01 (-0.02,0) 0.01 (0.00,0.03) 
Total CVD 
46.1  (45.5-46.8) 63.3  (62.9-63.8) 17.2 (13.9, 20.5) 1.37 (1.36-1.39) 5.02 (4.84,5.19) 1.18 (1.1,1.26) 0.23 (0.16,0.29) 
 
  
 
     
 
  
Index age 60   
 
 
    
 
  
Stable angina 
4.5  (4.3-4.7) 8.1  (7.9-8.4) 3.6 (3.3, 3.9) 1.81 (1.75-1.87) 0.76 (0.71,0.81) 0.36 (0.32,0.4) 0.00 (0.00,0.00) 
Unstable angina 
5.9  (5.6-6.2) 8.6  (8.3-8.9) 2.7 (2.4, 3.0) 1.45 (1.41-1.5) 0.61 (0.55,0.67) 0.24 (0.19,0.28) 0.00 (0.00,0.00) 
Myocardial infarction 
5.0  (4.8-5.2) 7.1  (6.9-7.4) 2.1 (1.8, 2.4) 1.43 (1.38-1.48) 0.46 (0.41,0.52) 0.24 (0.2,0.28) 0.01 (0.00,0.01) 
Unheralded CHD death 
1.9  (1.8-2.1) 2.4  (2.3-2.6) 0.5 (0.3, 0.7) 1.25 (1.18-1.32) 0.11 (0.07,0.14) 0.05 (0.03,0.08) 0.00 (0.00,0.01) 
Heart failure 
5.5  (5.2-5.9) 8.0  (7.7-8.3) 2.5 (2.1, 2.9) 1.45 (1.39-1.5) 0.47 (0.41,0.53) 0.17 (0.13,0.21) 0.01 (0.00,0.01) 
Cardiac arrest/SCD 
1.7  (1.6-1.9) 2.0  (1.9-2.2) 0.3 (0.1, 0.5) 1.16 (1.08-1.24) 0.08 (0.05,0.11) 0.01 (-0.01,0.04) 0.00 (0.00,0.00) 
Transient ischaemic attack 
5.9  (5.6-6.3) 6.6  (6.4-6.8) 0.6 (0.3, 1.0) 1.11 (1.07-1.15) 0.2 (0.13,0.26) 0.08 (0.04,0.13) 0.00 (0.00,0.00) 
Ischaemic stroke 
6.6  (6.3-7.0) 7.7  (7.5-8.0) 1.1 (0.7, 1.5) 1.16 (1.12-1.21) 0.27 (0.21,0.34) 0.1 (0.05,0.14) 0.00 (0.00,0.00) 
Subarachnoid haemorrhage 
0.5  (0.4-0.6) 0.7  (0.6-0.9) 0.3 (0.1, 0.4) 1.52 (1.27-1.77) 0.05 (0.03,0.07) 0.03 (0.02,0.05) 0.00 (0.00,0.00) 
Intracerebral haemorrhage 
0.9  (0.8-1.0) 1.3  (1.2-1.4) 0.4 (0.2, 0.5) 1.41 (1.3-1.53) 0.08 (0.05,0.1) 0.04 (0.02,0.06) 0.00 (0.00,0.00) 
Peripheral arterial disease 
4.4  (4.1-4.6) 5.9  (5.7-6.1) 1.5 (1.2, 1.8) 1.35 (1.3-1.4) 0.34 (0.29,0.39) 0.19 (0.15,0.23) 0.00 (0.00,0.00) 
Abdominal aortic aneurysm 
1.7  (1.5-1.9) 1.7  (1.5-1.8) 0.0 (-0.2, 0.2) 0.99 (0.92-1.06) 0.02 (-0.02,0.05) -0.01 (-0.04,0.01) 0.00 (0.00,0.00) 
Total CVD 44.6 (43.9-45.3) 60.2 (59.6-60.7) 15.6 (12.4-18.8) 1.35 (1.33-1.37) 3.44 (3.3,3.58) 1.5 (1.4,1.61) 0.03 (0.02,0.03) 
 
  
 
     
 
  
Index age 80   
 
 
    
 
  
Stable angina 
3.6  (3.4-3.8) 6.6  (6.3-6.8) 3 (2.7, 3.2) 1.84 (1.77-1.9) 0.31 (0.28,0.33) 0.16 (0.14,0.18) 0.00 (0.00,0.00) 
Unstable angina 
4.7  (4.5-5.0) 6.9  (6.6-7.2) 2.2 (1.9, 2.5) 1.46 (1.4-1.53) 0.23 (0.2,0.26) 0.1 (0.08,0.12) 0.00 (0.00,0.00) 
Myocardial infarction 
4.0  (3.8-4.2) 5.9  (5.6-6.1) 1.8 (1.6, 2.1) 1.45 (1.4-1.51) 0.19 (0.17,0.22) 0.11 (0.09,0.13) 0.00 (0.00,0.00) 
Unheralded CHD death 
1.8  (1.6-2.0) 2.3  (2.1-2.5) 0.5 (0.4, 0.7) 1.31 (1.21-1.41) 0.06 (0.05,0.08) 0.03 (0.02,0.05) 0.00 (0.00,0.00) 
Heart failure 
5.3  (4.9-5.7) 8.0  (7.6-8.4) 2.8 (2.4, 3.2) 1.53 (1.44-1.61) 0.31 (0.27,0.34) 0.12 (0.09,0.15) 0.00 (0.00,0.00) 
Cardiac arrest/SCD 
1.4  (1.2-1.5) 1.6  (1.5-1.7) 0.2 (0.1, 0.4) 1.17 (1.08-1.25) 0.03 (0.02,0.04) 0.01 (0,0.02) 0.00 (0.00,0.00) 
Transient ischaemic attack 
4.8  (4.5-5.1) 5.5  (5.3-5.7) 0.7 (0.4, 1.0) 1.14 (1.09-1.19) 0.09 (0.06,0.12) 0.04 (0.02,0.06) 0.00 (0.00,0.00) 
Ischaemic stroke 
5.8  (5.5-6.2) 7.1  (6.8-7.4) 1.3 (0.9, 1.6) 1.22 (1.16-1.27) 0.16 (0.12,0.19) 0.06 (0.04,0.09) 0.00 (0.00,0.00) 
Subarachnoid haemorrhage 
0.4  (0.4-0.5) 0.7  (0.6-0.8) 0.2 (0.1, 0.3) 1.6 (1.34-1.85) 0.03 (0.02,0.04) 0.02 (0.01,0.03) 0.00 (0.00,0.00) 
Intracerebral haemorrhage 
0.7  (0.6-0.8) 1.1  (1.0-1.2) 0.3 (0.2, 0.5) 1.46 (1.31-1.61) 0.04 (0.02,0.05) 0.02 (0.01,0.03) 0.00 (0.00,0.00) 
Peripheral arterial disease 
3.4  (3.2-3.6) 4.6  (4.4-4.8) 1.3 (1.0, 1.5) 1.38 (1.32-1.44) 0.14 (0.12,0.16) 0.08 (0.07,0.1) 0.00 (0.00,0.00) 
Abdominal aortic aneurysm 
1.4  (1.2-1.6) 1.5  (1.3-1.6) 0.0 (-0.1, 0.2) 1.03 (0.93-1.12) 0.01 (-0.01,0.03) -0.01 (-0.02,0.01) 0.00 (0.00,0.00) 
Total CVD 
37.3  (36.6-38.0) 51.7  (51.1-52.4) 14.4 (11.6-17.2) 1.39 (1.36-1.41) 1.59 (1.52,1.66) 0.75 (0.69,0.8) 0.00 (0.00,0.00) 
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Table S 5 Hazard ratios (95% CIs) for 10 mmHg higher systolic blood pressure adjusted for age and sex. 
Event HR Lower 
95% CI 
Upper 
95% CI 
Stable angina 1.19 1.18 1.20 
Unstable angina 1.13 1.11 1.15 
Myocardial infarction 1.15 1.14 1.16 
Unheralded CHD death 1.12 1.10 1.15 
Heart failure 1.12 1.11 1.14 
Cardiac arrest/SCD 1.10 1.07 1.12 
Transient ischaemic attack 1.07 1.06 1.08 
Ischaemic stroke 1.16 1.14 1.18 
Intracerebral haemorrhage 1.20 1.17 1.23 
Subarachnoid haemorrhage 1.18 1.13 1.23 
Peripheral arterial disease 1.16 1.15 1.18 
Abdominal aortic aneurysm 1.02 1.00 1.05 
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Figure S 1 Study flow diagram
Patients excluded: 
 Missing sex = 135 
 Age <30 years = 1,858,924 
 <1 year follow-up prior to study entry = 709,006 
 History of CVD prior to entry date = 159,239 
 Pregnant within 6 months of eligibility date =39,018 
4,703,682 patients met research quality standards 
1,258,006 patients included 
679,354 no baseline blood pressure measurement 
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Figure S 2 The distribution of demographic characteristics among primary care practices contributing to the main analysis. 
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Figure S 3 Hazard ratios (95% CIs) per 10 mmHg higher mid blood pressure (mid-BP), mean arterial blood pressure 
(MAP) and pulse pressure (PP) adjusted for age and sex.* 
 
*Adjustments include age, quadratic age, and stratification by sex and primary care practice. Confidence intervals are Bonferroni-
corrected (3 variables X 12 endpoints = 36 tests in total). 
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Figure S 4 Hazard ratios (95% CIs) by sex per 20/10 mmHg higher systolic or diastolic blood pressure adjusted for age.* 
 
*Models were fitted separately for men and women and included continuous age, quadratic age, with stratification by primary care 
practice. Confidence intervals are Bonferroni-corrected (2 sexes X 12 endpoints=24 tests).  
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Figure S 5 Adjusted hazard ratios (95% CIs) per 20/10 mmHg higher systolic or diastolic blood pressure.*  
 
Abbreviations: BP meds, blood pressure lowering medications; lipids include total and HDL cholesterol.  
*All models included continuous age, quadratic age, with stratification by sex and primary care practice, in addition to the 
covariates listed above. Confidence intervals are Bonferroni-corrected (4 models X 12 endpoints=48 tests).  
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Figure S 6 Hazard ratios (95% CIs) per 20 mmHg higher systolic blood pressure adjusted for age and sex estimated 
separately in people with (N= 265,473) or without (N= 992,533) BP-lowering drugs at baseline.* 
 
*Models were fitted separately in people treated or not treated with BP medications at baseline, with adjustments for age, quadratic 
age, and stratification by sex and primary care practice. Confidence intervals are Bonferroni-corrected (2 groups X 12 endpoints=24 
tests in total). 
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Figure S 7 Hazard ratios (95% CIs) per 10 mmHg higher diastolic blood pressure adjusted for age and sex estimated 
separately in people with (N= 265,473) or without (N= 992,533) BP-lowering drugs at baseline. 
 
*Models were fitted separately in people treated or not treated with BP medications at baseline, with adjustments for age, quadratic 
age, and stratification by sex and primary care practice. Confidence intervals are Bonferroni-corrected (2 groups X 12 endpoints=24 
tests in total). 
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Figure S 8 Hazard ratios (95% CIs) for the associations of different cutoffs of systolic blood pressure (reference 115 
mmHg) with cardiovascular endpoints in men adjusted for age (BP was modelled as a continuous variable using splines 
with 3 knots). 
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Figure S 9 Hazard ratios (95% CIs) for the associations of different cutoffs of diastolic blood pressure (reference 75 
mmHg) with cardiovascular endpoints in men adjusted for age (BP was modelled as a continuous variable using splines 
with 3 knots). 
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Figure S 10 Hazard ratios (95% CIs) for the associations of different cutoffs of systolic blood pressure (reference 115 
mmHg) with cardiovascular endpoints in women adjusted for age (BP was modelled as a continuous variable using splines 
with 3 knots). 
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Figure S 11 Hazard ratios (95% CIs) for the associations of different cutoffs of diastolic blood pressure (reference 75 
mmHg) with cardiovascular endpoints in women adjusted for age (BP was modelled as a continuous variable using splines 
with 3 knots). 
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Figure S 12 Hazard ratios (95% CIs) for the associations of different cutoffs of systolic blood pressure (reference 115 
mmHg) with cardiovascular endpoints in people not receiving blood pressure medications at baseline adjusted for age (BP 
was modelled as a continuous variable using splines with 3 knots). 
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Figure S 13 Hazard ratios (95% CIs) for the associations of different cutoffs of diastolic blood pressure (reference 75 
mmHg) with cardiovascular endpoints in people not receiving blood pressure medications at baseline adjusted for age (BP 
was modelled as a continuous variable using splines with 3 knots). 
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Figure S 14 Hazard ratios (95% CIs) for the associations of different cutoffs of diastolic blood pressure (reference 75 
mmHg) with cardiovascular endpoints in people receiving blood pressure medications at baseline adjusted for age (BP was 
modelled as a continuous variable using splines with 3 knots). 
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Figure S 15 Hazard ratios (95% CIs) for the associations of different cutoffs of systolic blood pressure (reference 115 
mmHg) with cardiovascular endpoints in people receiving blood pressure medications at baseline adjusted for age (BP was 
modelled as a continuous variable using splines with 3 knots). 
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Figure S 16 Lifetime risk of 12 different cardiovascular diseases in men and women with normal blood pressure or 
hypertension* at index age 30. 
*hypertension defined as systolic blood pressure ≥140 or diastolic blood pressure ≥ 90 mmHg or use of 
blood pressure lowering treatments or physician-recorded diagnosis at baseline. 
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Figure S 17 Years of life lost to cardiovascular disease up to age 95 years in men and women associated with hypertension 
at index age 30, 60 and 80, adjusted for sex, smoking, diabetes, and total and HDL cholesterol. 
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Results from sensitivity analyses 
Figure S 18 Evaluation of heterogeneity* at practice level of the associations of different cardiovascular outcomes with 
20/10 mmHg increase in systolic/diastolic blood pressure. 
 
*Estimates of fixed effects are equivalent to those reported in the main analysis (but differ slightly because unlike in 
the main analysis were practices with at least 1 event contributed to the estimates, here we have considered studies 
with 2 or more for modelling purposes). Estimates of random effects account for practice level heterogeneity; 
differences between fixed effects and random effects signify that the heterogeneity impacts on the overall assocaitions. 
The prediction interval expresses uncertainty about the association in a randomly chosen practice.1 
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Figure S 19 Hazard ratios (95% CIs) per 20/10 mmHg higher systolic or diastolic blood pressure adjusted for age and sex, 
using end points from different sources. 
 
  
In the main analysis all 3 sources of end points are used (primary care, secondary care and death records). To compute endpoints 
based on secondary care and mortality (second row where applicable) patients were followed up until a hospital admission or 
death for the specified event, ignoring diagnoses/events recorded in primary care. Similarly, for mortality endpoints patients were 
followed up until death, ignoring non-fatal presentations. The majority of deaths from stroke are unclassified (not included in the 
mortality estimate from ischaemic stroke shown here). 
  
28 
 
Figure S 20 Age and sex adjusted hazard ratios (95% CIs) for 20 mmHg higher systolic blood pressure according to the 
number of BP measurements taken within 2 years of baseline (1 or more [as in the main analysis], only 1, or 2 or more). 
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Figure S 21 Age and sex adjusted hazard ratios (95% CIs) for 20 mmHg higher systolic blood pressure based on a single 
measurement closest to the baseline (within 2 years of baseline). 
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Figure S 22 Age and sex adjusted hazard ratios (95% CIs) for 20 mmHg higher systolic blood pressure based on imputed 
and observed (main analysis) blood pressure levels.  
 
Dataset including observed and imputed BP, N= 1,937,360 patients; complete cases for SBP (as in main analysis) N= 1,258,006 
patients. 
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Supplementary methods 
Multiple imputation 
Supplementary methods 
Multiple imputation 
Multiple imputation
1
 was implemented using the mice algorithm in the statistical package R.  Imputation models were estimated 
separately for men and women and included:  
 
a) all the baseline covariates used in the main analysis (age, quadratic age, diabetes, smoking, systolic blood pressure, diastolic 
blood pressure, mean arterial pressure, pulse pressure, total cholesterol, HDL cholesterol, body mass index), 
 
b) prior (between 1 and 4 years before study entry) and post (between 0 and 1 year after study entry) averages of continuous main 
analysis covariates and other measurements not in the main analysis (white cell count, haemoglobin, creatinine, alanine 
transferase), 
 
c) baseline medications (statins, blood pressure medications, aspirin, oral contraceptives and hormone replacement therapy),  
 
d) coexisting medical conditions (history of depression, cancer, renal disease, liver disease and chronic obstructive pulmonary 
disease),  
 
e) the Nelson-Aalen hazard and the event status for each endpoint analysed in the data
2
.  
 
Non-normally distributed variables were log-transformed for imputation and exponentiated back to their original scale for 
analysis. Five multiply imputed datasets were generated, and Cox models fitted to each dataset. Coefficients were combined using 
Rubin’s rules.  
We checked whether the imputations were plausible by comparing plots of the distribution of observed and imputed values of all 
variables. We checked whether the exclusion of patients with no blood pressure measurements (within two years of the baseline) 
biased the reported associations with cardiovascular diseases by comparing hazard ratios estimated based on imputed data (Figure 
S22).  
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Estimation of lifetime risks and years of life-lost 
We estimated lifetime risks of each cardiovascular disease adjusted for the competing risk of other cardiovascular diseases and 
non-CVD mortality based on Cox models with age as the timescale. For a given disease q this involves a) estimating separate Cox 
models for events of disease q and for the competing events1,…,q-1,q+1,…,Q including the same predictor variables, b) 
multiplying the hazard contribution for disease q at a given age by the probability of being still at risk and not having experienced 
a competing event by that age, and c) computing the cumulative incidence (sum of hazards) between the baseline age (age at entry 
to study) and age 95 (‘lifetime’).  
Thus, for individual i the lifetime risk of experiencing disease q from baseline age tito attained ageti+T in the presence of the 
competing risks is given by:  
  ( )  ∫    ( ) 
         [– ∫ ∑    ( ) 
          
    
  
]   
    
  
                                 [1] 
where    ( ) is the baseline hazard for disease q at age t 
   is a vector of coefficients for cause q 
   is the vector of covariates for individual i 
   ( ) 
     is the hazard for disease k for individual i at age t given covariates xi 
Expression [1] is estimated by replacing coefficients and baseline hazards by their estimates. Because the baseline hazard is 
estimated as a step function, the integrals are replaced by sums over event times. 
 
Suppose the two curves in Figure S1 represent the lifetime risk of a 30-year old individual with normal BP (black line) or 
hypertension (red dashed line) at the baseline measurement. The years of life lost (YLL) are estimated from the difference in the 
area under the two curves, i.e.:  
    ∫ {  ( )    ( )}  
  
  
                                                 [2] 
where  ( )  and   ( ) represent risk estimates up to age  u (estimated by expression [1] and adjusted for other risk factors  
(baseline age, sex, diabetes, smoking status, total cholesterol, HDL cholesterol) assuming normal blood pressure or hypertension 
respectively, averaged over individuals in the data. We estimated {2} by applying the trapezium rule in intervals of u=0.5 years, 
from the baseline age to age 95. 
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